Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory

We came across a bearish thesis on Capricor Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on CAPR. Capricor Therapeutics, Inc.'s share was trading at $26.55 as of December 15th. Telix Pharma (TLX) Makes Progress With New Study Capricor Therapeutics, Inc., a clinical-stage biotechnology company, develops transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and oth ...